Uncategorized
No serious adverse events seen with gene therapy for X-linked retinoschisis
Patients with X-linked retinoschisis who underwent treatment with adeno-associated virus-based gene therapy developed no treatment-related serious adverse events through 12 months, according to interim safety data from a phase 1/2 trial.Safety data for 12 of 27 patients treated with adeno-associated virus-based gene therapy (Applied Genetic Technologies Corporation) showed that the treatment is generally well tolerated through 1 year, according to a presentation by Mark E. Pennesi, MD, PhD, at the Macula Society annual meeting in Singapore.